Additionally, miR-199a was shown to target PARP-1 and activate the ERK1/2 pathway to promote IL-10 production, suggesting that miR-199a may be a potential therapeutic target of systemic lupus erythematosus (Su et al. 2019). This evidence concerns the gene MAPK3 and systemic lupus erythematosus.